BioLineRx to Report Third Quarter 2026 Results on November 23, 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioLineRx (BLRX) will release its unaudited third-quarter 2026 financial results on November 23, 2026, before U.S. markets open. The quarter ended September 30, 2026. Chief Executive Officer Philip Serlin will speak on the 8:30 a.m. EST conference call that day.
The company’s event page will carry a live webcast, with a replay available approximately two hours after the call ends. A separate dial-in replay will be available through November 25, 2026.
Key Figures
- Results release date
- November 23, 2026
- Third-quarter 2026 unaudited financial results; before U.S. markets open
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management to Hold Conference Call at 8:30 a.m. EST
The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.
To access the conference call, please dial +1-888-407-2553 from the
About BioLineRx
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's lead development asset is GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial has been initiated in the first quarter of 2026. GLIX1 is being developed under a collaboration with Hemispherian AS.
The Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained the rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer (PDAC), and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.
Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.
CONTACTS:
United States
Chuck Padala
LifeSci Advisors, LLC
IR@biolinerx.com
Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2026-results-on-november-23-2026-302943733.html
SOURCE BioLineRx Ltd.